Previous 10 | Next 10 |
home / stock / govxw / govxw news
Letter from CEO Describes Achievements during 2021 and Sets Forth New Goals for 2022 ATLANTA, GA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines a...
Ongoing Phase 1/2 Trial Advancing to Phase 2 Evaluation of Multi-Antigen Vaccine, Targeting both Spike and Nucleocapsid Proteins, as a Universal Booster to Current FDA-Approved Vaccines ATLANTA, GA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. ...
The GeoVax Multi-antigenic MVA-VLP Approach Designed to Provide a Stronger, Broader Protection Atlanta, GA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and va...
Nonhuman Primate Testing of Sudan and Marburg Vaccine Candidates Demonstrates Efficacious Immune Response ATLANTA, GA, Dec. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccine...
GEO-CM02 Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants such as Omicron ATLANTA, GA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vacc...
GEO-CM02 Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants ATLANTA, GA, Nov. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and canc...
GeoVax Intellectual Property Portfolio Includes More than 70 Granted/Pending Patent Applications Atlanta, GA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and ...
ATLANTA, GA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it will be represented during presentations at the following upcomi...
Progress in Clinical Development of COVID-19 and Immuno-Oncology Programs ATLANTA, GA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious disease...
Phase 2 Vaccine Designed to Enhance Response for Immunocompromised Patients Complements GeoVax’s Pan-Coronavirus Vaccine Program ATLANTA, GA and DUARTE, CA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs Inc. (Nasdaq: GOVX), ...
News, Short Squeeze, Breakout and More Instantly...
GeoVax Labs Inc. Warrants Company Name:
GOVXW Stock Symbol:
NASDAQ Market:
GeoVax Labs Inc. Warrants Website:
Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced ...
ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will presen...
ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 36t...